Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets

NCT01366352 · View on ClinicalTrials.gov ↗

Study Summary

This was a single-center, double-blind, randomized, cross-over Phase 1 study in normal, healthy volunteers. Study treatment entailed single doses of two different formulations of MNTX tablets.

Conditions Studied

Interventions

  • DRUG MNTX tablet (Formulation 1)
  • DRUG MNTX tablet (Formulation 2)

Study Locations (1)

New York

  • Progenics Pharmaceuticals, Inc. — Tarrytown

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2004-02
Est. Completion 2004-03
Phase Phase 1

Sponsor

Bausch Health Americas

55 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01366352

The ClinicalTrials.gov registry entry for NCT01366352 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 55 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Normal Volunteers appearing as the primary indexed condition, and to 2 interventions — of which MNTX tablet (Formulation 1) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01366352 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01366352 about?

NCT01366352 is a clinical study titled "Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets". This was a single-center, double-blind, randomized, cross-over Phase 1 study in normal, healthy volunteers. Study treatment entailed single doses of two different formulations of MNTX tablets.

What is the current status of trial NCT01366352?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2004-02. Estimated completion is 2004-03.

What conditions does trial NCT01366352 study?

This clinical trial studies the following conditions: Normal Volunteers. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01366352?

The interventions under investigation include: MNTX tablet (Formulation 1) (DRUG), MNTX tablet (Formulation 2) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01366352?

This trial is sponsored by Bausch Health Americas, which has 55 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01366352 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial